RxDoctor Payments Data

Zurab Nadareishvili, MD

Vascular Neurology · Washington, DCNPI 1588812713

Payments from drug & device makers

$464in general payments, 2019–2025

Across 16 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$122
  • Stryker$107
  • Amgen$54
  • AstraZeneca$48
  • Neurelis, Inc.$37
  • Chiesi USA, Inc.$29
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)5$122
Stryker1$107
Amgen2$54
AstraZeneca2$48
Neurelis, Inc.2$37
Chiesi USA, Inc.1$29
Lilly USA, LLC1$28
UCB, Inc.1$21
CSL Behring1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$78,850
Medicare patients
245
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular neurology in Washington

Where these figures come from

Is this you, or does something look wrong? →